Chemistry: analytical and immunological testing – Cancer
Reexamination Certificate
2001-12-17
2008-11-18
Wallenhorst, Maureen M (Department: 1797)
Chemistry: analytical and immunological testing
Cancer
C436S056000, C436S063000, C436S164000, C436S172000, C436S813000, C435S004000, C435S007100, C435S007210, C435S007230, C435S040500, C702S019000
Reexamination Certificate
active
07452727
ABSTRACT:
The present invention relates to an automatable method for the improved diagnosis of pathologically altered cells by simultaneously staining at least two different molecular markers, which exhibit a change in gene expression which is disease-associated, in a cell or constituent regions of a tissue sample by means of using combinations of antibodies and accrediting signal intensities.
REFERENCES:
patent: 5109429 (1992-04-01), Bacus et al.
patent: 5544650 (1996-08-01), Boon et al.
patent: 5733721 (1998-03-01), Hemstreet et al.
patent: 5741648 (1998-04-01), Hemstreet et al.
patent: 5932412 (1999-08-01), Dillner et al.
patent: 6005256 (1999-12-01), McGlynn et al.
patent: 6007996 (1999-12-01), McNamara et al.
patent: 6077996 (2000-06-01), Klenke
patent: 6248063 (2001-06-01), Barnhill et al.
patent: 2002/0123845 (2002-09-01), Henning et al.
patent: 9921014 (1999-04-01), None
patent: 0024760 (2000-05-01), None
Williams, G., Romanowski, P., Morris, L., Madine, M., Mills, A., Stoeber, K., Marr, J., Laskey, R., Coleman, N., “Improved Cervical Smear Assessment Using Antibiotics Against Proteins That Regulate DNA Replication”, Proc. Natl. Acad. Sci. USA, 95: 14932-14937 (Dec. 1998).
Cuzick, J., “Human Papillomavirus Testing For Primary Cervical Cancer Screening”, JAMA, 283: 108-109 (Jan. 2000).
Tervahauta, A., Syrjanen, S., Mantyjarvi, R., Syrjanen, K., “Detection of p53 Protein and Ki-67 Proliferation Antigen in Human Papillomavirus (HPV)-Positive and HPV-Negative Cervical Lesions by Immunohistochemical Double-staining”, Cytopathology, 5: 282-293 (1994).
Boon, M., Beck, S., Kok, L., “Semiautomatic PAPNET Analysis of Proliferating (MiB-1-Positive) Cells in Cervical Cytology and Histology”, Diag. Cytopathology, 13: 423-428 (1995).
Sawaya, G., Washington, A., “Cervical Cancer Screening: Which Techniques Should Be Used and Why?”, Clin. Obstetrics and Gynecology, 42: 922-938 (1999).
Sano, T., Oyama, T., Kashiwabara, K., Fukuda, T., Nakajima, T., “Immunohistochemical Overexpression of p16 Protein Associated with Intact Retinoblastoma Protein Expression in Cervical Cancer and Cervical Intraepithelial Neoplasia”, Path. Int., 48: 580-585 (1998).
Gomez, F., Roldan, M., Corcuera, M., Picazo, A., Munoz, E., Alonso, M., “Simultaneous Detection of Antigens and Specific DNA Sequences of Human Papillomavirus in Uterine Cervical Biopsy Specimens. Description of a Double-Labelling Techniquel”, Eur. J. Histochem., 41: 255-259 (1997).
Stoler, M., “Advances in Cervical Screening Technology”, Mod. Pathol., 13: 275-284 (2000).
Leek, R., Kaklamanis, L., Pezzella, F., Gatter, K., Harris, A., “bcl-2 in Normal Human Breast and Carcinoma, Association With Oestrogen Receptor-Positive, Epidermal Growth Factor Receptor-Negative Tumours and In Situ Cancer”, Br. J. Cancer, 69: 135-139 (1994).
Oshika, Y., Nakamura, M., Tokunaga, T., Fukushima. Y., Abe, Y., Ozeki, Y., Yamazaki, H., Tamaoki, N., Ueyama, Y., “Multidrug Resistance-Associated Protein and Mutant p53 Protein Expression in Non-Small Cell Lung Cancer”, Mod. Pathol., 11: 1059-1063 (1998).
Kraeft, S., Sutherland, R., Gravelin, L., Hu, G., Ferland, L., Richardson, P., Elias, A., Chen, L., “Detection and Analysis of Cancer Cells in Blood and Bone Marrow Using a Rare Event Imaging System”, Clin. Cancer Research, 6: 434-442 (Feb. 2000).
Reiner, A., Neumeister, B., Spona, J., Reiner, G., Schemper, M., Jakesz, R., “Immunoyctochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer”, Cancer Research, 50: 7057-7061 (Nov. 1990).
Mokbel, K., Parris, C., Ghilchik, M., Williams, G., Newbold, R., “The Association Between Telomerase, Histopathological Parameters, and KI-67 Expression in Breast Cancer”, Am. J. Surgery, 178: 69-72 (1999).
Rao, J., Apple, S., Hemtreet, G., Jin, Y., Nieberg, R., “Single Cell Multiple Biomarker Analysis in Archival Breast Fine-Needle Aspiration Specimens: Quantitative Fluorescence Image Analysis of DNA Content, p53, and G-actin as Breast Cancer Biomarkers”, Cancer Epidemiology, Biomarkers & Prevention, 7: 1027-1033 (1998).
Valdiguie, P., “Role and Use of Expert Systems Within the Clinical Laboratory”, Clinica Chimica Acta, 278: 193-202 (1998).
Neel, T., Moreau, A., Laboisse, C., Truchaud, A., “Comparative Evaluation of Automated Systems in Immunohistochemistry”, Clinica Chimica Acta, 278: 185-192 (1998).
Hopman, A., “Rapid Synthesis of Biotin-, Digoxigenin-, Trinitrophenyl-, and Fluorochrome-Labeled Tyramides and Their Application for In Situ Hybridization Using CARD Amplification”, J. of Histochem. & Cytochem., 46: 771-777 (1998).
Bergeron, C., “Human Papillomaviruses Associated with Cervical Intraepithelial Neoplasia”, Am. J. Surgical Pathology, 16(7): 641-649, 1992.
Busmanis, I., “Biomarkers in Carcinoma of the Cervix, Emphasis on Tissue-related Factors and their Potential Prognostic Factors”, Ann. Acad. Med. Singapore, 27: 641-645, 1998.
Skomedal, H., “Aberrant Expression of the Cell Cycle Associated Proteins TP53, MDM2, p21, p27, cdk4, Cyclin D1, RB and EGFR in Cervical Carcinomas”, Gynecologic Oncology 73: 223-228, 1999.
Mitra, “ERBB2 (HER2
eu) Oncogene is Frequently Amplified in Squamous Cell Carcinoma of the Uterine Cervix”, Cancer Research 54: 637-639, 1994.
Radhakrishna Pillai, M., “The Presence of Human Papillomavirus-16/-18 E6, p53, and Bcl-2 protein in Cervicovaginal Smears from Patients with Invasive Cervical Cancer”, Cancer Epidemiology, Biomarkers & Prevention, 5: 239-335, May 1996.
Kersemaekers, A.-M., “Oncogene Alterations in Carcinomas of thew Uterine Cervix: Overexpression of the Epidermal Growth Factor Receptor is Associated with Poor Prognosis”, Clinical Cancer Research, 5: 577-586, Mar. 1999.
Munirajan, A.K., “The Status of Human Papillomavirus and Tumor Suppressor Genes p53 and p16 in Carcinomas of Uterine Cervix from India”, Gynecologic Oncology 69: 205-209, 1998.
Bohmann Kerstin
Hennig Guido
Schopper Birge
Wirtz Ralph
Siemens Corporation
Siemens Healthcare Diagnostics Inc
Wallenhorst Maureen M
LandOfFree
Method for increasing clinical specificity when detecting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing clinical specificity when detecting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing clinical specificity when detecting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4051023